DOE Funds Molten Chloride Reactor Experiment, ASP Isotopes Plans Uranium Enrichment Plant
Molten Chloride Reactor Experiment Receives Funding
The U.S. Department of Energy (DOE) has approved cost-shared funding for the final stage of the Molten Chloride Reactor Experiment (MCRE) through its Advanced Reactor Demonstration Program. This funding supports work by Southern Company, Idaho National Laboratory, and CORE POWER to advance molten salt reactor technology.
The MCRE aims to be the first fast-spectrum molten chloride salt reactor experiment to achieve criticality. It is expected to provide data on fuel behavior, reactor operation, and performance, which will inform future reactor design, licensing, and commercial deployment. The project seeks to reduce technical risks and expand understanding of fast-spectrum molten salt systems, potentially accelerating innovation for various reactor developers.
Fast-spectrum molten salt reactors could extend beyond electricity generation to power industrial processes, produce medical isotopes, enable maritime propulsion, and extract value from used nuclear fuel. Future designs could utilize actinides from spent nuclear fuels to generate more energy and reduce nuclear waste volume and longevity. Some configurations may also support fuel breeding and medical isotope production. The MCRE itself will not use spent fuel, demonstrate a closed fuel cycle, or test a marine reactor.
ASP Isotopes and Necsa Plan Uranium Enrichment Facility
South Africa’s Necsa and a subsidiary of ASP Isotopes have signed a binding framework for a nuclear fuel venture. The venture, Quantum Leap Energy, would be approximately 80% owned by Quantum Leap Energy and 20% by Necsa. The proposed Pelindaba facility in South Africa would produce enriched uranium for advanced reactors, with TerraPower identified as a future buyer.
Supply agreements between TerraPower and ASP Isotopes are in place for the fuel the venture expects to produce. Quantum Leap Energy would manage operations and capital, while Necsa would provide site access, nuclear safeguards, and regulatory support. The project's cost, production capacity, and commissioning date have not been disclosed. ASP Isotopes noted that its enrichment technologies have not yet been applied to uranium-235, and the project requires further testing, financing, and regulatory approvals.